Surufatinib Plus mFOLFIRINOX and PD-1 Inhibitor as the Neoadjuvant Therapy for High-risk or Borderline Resectable Pancreatic Cancer

NCT07469956 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Pancreatic Cancer Resectable

Interventions

DRUG: Surufatinib
DRUG: Toripalimab
DRUG: mFOLFIRINOX

Sponsor

Sun Yat-sen University